Literature DB >> 16403066

Paced electrogram fractionation analysis of arrhythmogenic tendency in DeltaKPQ Scn5a mice.

Catherine E Head1, Richard Balasubramaniam, Glyn Thomas, Catharine A Goddard, Ming Lei, William H Colledge, Andrew A Grace, Christopher L-H Huang.   

Abstract

INTRODUCTION: Gain-of-function mutations within Scn5a, including the DeltaKPQ 1505-1507 deletion in the inactivation domain compromising myocardial repolarization, are implicated in human long QT 3 syndrome (LQT3), associated with ventricular arrhythmogenesis and sudden death. METHODS AND
RESULTS: Patch clamp studies on isolated ventricular Scn5a+/Delta myocytes from DeltaKPQ mice produced by homologous recombination in embryonic stem (ES) cells confirmed such altered electrophysiological properties of the mutant channel. Programmed electrical stimulation (PES) with decremental pacing from the basal right ventricular epicardial surface and paced electrogram fractionation analysis (PEFA) of electrograms recorded from the basal left ventricular epicardial surface of Langendorff-perfused whole heart preparations demonstrated ventricular tachycardia (VT) in 8 of 9 Scn5a+/Delta mutant (but no Scn5a+/+ (wild-type (WT)) controls; n = 17), with increased electrogram durations (EGD) and more dispersed conduction curves. Isoproterenol (100 nM) was without effect on tachycardic Scn5a+/Delta hearts (n = 9) yet propranolol (1 microM) prevented VT in all isoproterenol-infused WT control (n = 4) but no Scn5a+/Delta hearts (n = 4). Furthermore propranolol itself increased EGD and dispersion in Scn5a+/Delta hearts. In contrast, mexiletine (10 microM) suppressed VTs in 4 of 5 Scn5a+/Delta hearts without altering EGD or dispersion.
CONCLUSION: Beta-adrenoreceptor blockade does not confer an antiarrhythmic effect and may even enhance arrhythmogenesis by increasing reentrant substrate in Scn5a+/Delta hearts while mexiletine protects against VT without modifying conduction characteristics. Together these findings permit a scheme where VT in LQT3 is initiated by triggered mechanisms but propagated by reentry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16403066     DOI: 10.1111/j.1540-8167.2005.00200.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  34 in total

1.  Ventricular arrhythmogenesis following slowed conduction in heptanol-treated, Langendorff-perfused mouse hearts.

Authors:  Gary Tse; Sandeep S Hothi; Andrew A Grace; Christopher L-H Huang
Journal:  J Physiol Sci       Date:  2012-01-05       Impact factor: 2.781

2.  Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling.

Authors:  Rebecca C Ahrens-Nicklas; Colleen E Clancy; David J Christini
Journal:  Cardiovasc Res       Date:  2009-03-05       Impact factor: 10.787

3.  Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3.

Authors:  Larissa Fabritz; Dierk Damke; Markus Emmerich; Susann G Kaufmann; Kathrin Theis; Andreas Blana; Lisa Fortmüller; Sandra Laakmann; Sven Hermann; Elena Aleynichenko; Johannes Steinfurt; Daniela Volkery; Burkhard Riemann; Uwe Kirchhefer; Michael R Franz; Günter Breithardt; Edward Carmeliet; Michael Schäfers; Sebastian K G Maier; Peter Carmeliet; Paulus Kirchhof
Journal:  Cardiovasc Res       Date:  2010-01-28       Impact factor: 10.787

4.  Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome.

Authors:  Ian N Sabir; Lucia M Li; Victoria J Jones; Catharine A Goddard; Andrew A Grace; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2007-09-06       Impact factor: 3.657

5.  The SCN5A mutation A1180V is associated with electrocardiographic features of LQT3.

Authors:  Yanmin Zhang; Juanli Wang; Suer Chang; Nan Zhou; Haijian Xing; Lei Wang; Chen Huang; Aiqun Ma; Christopher L-H Huang; Ming Lei; James A Fraser
Journal:  Pediatr Cardiol       Date:  2013-08-21       Impact factor: 1.655

6.  Empirical correlation of triggered activity and spatial and temporal re-entrant substrates with arrhythmogenicity in a murine model for Jervell and Lange-Nielsen syndrome.

Authors:  Sandeep S Hothi; Glyn Thomas; Matthew J Killeen; Andrew A Grace; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2009-05-09       Impact factor: 3.657

Review 7.  Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.

Authors:  Samantha C Salvage; Karthik H Chandrasekharan; Kamalan Jeevaratnam; Angela F Dulhunty; Andrew J Thompson; Antony P Jackson; Christopher L-H Huang
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

Review 8.  Murine Electrophysiological Models of Cardiac Arrhythmogenesis.

Authors:  Christopher L-H Huang
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

9.  A quantitative analysis of the effect of cycle length on arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts.

Authors:  Ian N Sabir; James A Fraser; Thomas R Cass; Andrew A Grace; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2007-04-17       Impact factor: 3.657

10.  Arrhythmogenic actions of the Ca2+ channel agonist FPL-64716 in Langendorff-perfused murine hearts.

Authors:  Nina S Ghais; Yanmin Zhang; Andrew A Grace; Christopher L-H Huang
Journal:  Exp Physiol       Date:  2008-10-31       Impact factor: 2.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.